
ESMO 2021 Industry Satellite Symposium



Advances in Antibody Drug Conjugates in Solid Tumors: Current Treatments and Emerging Therapies

Saturday, September 18, 2021 | Channel 3 | 18:45-20:15 CEST

Objectives

- To provide an update on the current treatment landscape surrounding ADCs in solid tumors
- To discuss recent advances in ADC technology
- To share the clinical data with novel ADCs in solid tumors to date

Johann de Bono, MBChB, FRCP, MSc, PhD, FMedSci

Institute of Cancer Research London, UK



Nadia Harbeck, MD, PhD

Breast Center, Dept. OB&GYN and CCC^{Munich}
LMU University Hospital
Munich, Germany



Salvatore Siena, MD

Niguarda Cancer Center Milan, Italy



Benjamin Levy, MD

Johns Hopkins Sidney Kimmel Cancer Center Sibley Memorial Hospital Washington, DC, USA



Agenda:

18:45-19:00 CEST Introduction to ADCs: Advancements in the Treatment of Solid Tumors with ADCs
19:00-19:20 CEST Recent Clinical Data With ADCs in NSCLC

19:20-19:40 CEST Latest Findings From Clinical Trials in Breast Cancer With ADCs

19:40-20:00 CEST Novel Clinical Experiences With ADCs in CRC and Gastric Cancer

20:00-20:15 CEST Live Q&A Session

Johann de Bono, MBChB, FRCP, MSc, PhD, FMedSci

Benjamin Levy, MD

Nadia Harbeck, MD, PhD

Salvatore Siena, MD

Faculty Panel



This symposium is intended for HCPs and may discuss agents and products in development. This Industry Satellite Symposium is organized and sponsored by Daiichi-Sankyo.

©2021 Daiichi-Sankyo, Inc. GLM-GCS-MONC-0087 06/21